Entera Bio Ltd.
Public company- Headquarters
- JERUSALEM
- Industry
- Biotechnology
- Ticker
- ENTX
- CIK
- 0001638097
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Class II directorJuan Camilo Arjona Ferreira, M.D. | Oct 27, 2026 | Appointed |
| directorHaya Taitel | Oct 27, 2026 | Departed |
| Class I directorLaura Hamill | Oct 6, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- CRISPR Therapeutics AG
CFO appointed: Andrew J. Silver
- BioNTech SE
WARN notice: Gaithersburg, MD
- ANAVEX LIFE SCIENCES CORP.
CEO appointed: Terrie Kellmeyer, Ph.D.
- RECURSION PHARMACEUTICALS, INC.
Chair of the Board appointed: Fred Hassan
- Executive appointment
Class II director appointed: Juan Camilo Arjona Ferreira, M.D.
Juan Camilo Arjona Ferreira, M.D. was named Class II director of Entera Bio Ltd., effective December 1, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 27, 2026Role: Class II director
- Executive departure
director departs: Haya Taitel
Haya Taitel, director of Entera Bio Ltd., departs the role, effective December 1, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 27, 2026Role: director
- Executive appointment
Class I director appointed: Laura Hamill
Laura Hamill was named Class I director of Entera Bio Ltd., effective December 1, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 6, 2026Role: Class I director
- Executive departure
director departs: Yonatan Malca
Yonatan Malca, director of Entera Bio Ltd., departs the role, effective December 1, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 6, 2026Role: director
Last verified Nov 8, 2026